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j ourna l homepage: www.e lsev ie r .com/ locate /goreCorrespondenceGenetic counseling and testing for hereditary
cancer risk in young adult women: Facilitating
autonomy and informed decision making is keyWe read with interest the Society of Gynecologic Oncology's (SGO)
statement on risk assessment for inherited gynecologic cancer predis-
positions (Lancaster et al., 2015). We commend the authors for their
comprehensive and thoughtful review of genetic counseling and testing
issues. However, we respectfully disagree with the SGO's position to
“not recommend genetic testing of women under age 21 for HBOC [He-
reditary Breast &Ovarian Cancer] or Lynch [syndrome] in the absence of
a family history of extremely early-onset cancer.” To be clear, we are not
advocating for routine testing in minor children, but are concerned
about the recommendation speciﬁcally as it applies to 18 to 20 year-
old women.
The authors correctly state that because the cancer risks in HBOC
syndrome (due to BRCA1 and BRCA2 [BRCA] mutations) and Lynch
syndrome are very low in women under age 21, management recom-
mendations are generally unchanged. The authors also state their con-
cern about the “potential negative consequences of genetic testing”
(Lancaster et al., 2015). Based on these two reasons, the SGO made
the recommendation that, with rare exceptions based on family history
presentation, young adult women should not be tested for these cancer
susceptibility gene mutations.
We believe that discussing and potentially offering genetic testing to
high risk women age 18 and older is appropriate in the context of pre-
test genetic counseling and informed consent regardless of the ages of
cancer diagnoses in their family. For simplicity, we frame our position
as it applies to the example of 18 to 20 year-old unaffected women
whohave a biological relativewith an identiﬁed BRCAmutation. If amu-
tation is present in a ﬁrst-degree relative, then these young women
have a 50% risk of testing positive. In addition, we assume that no rela-
tives have been affected with an “extremely early-onset cancer”
(e.g., breast or ovarian cancer diagnosed before age 30). We believe
that the general arguments discussed below apply also to those at-risk
for Lynch syndrome and other hereditary cancer predisposition
syndromes.
There are several strong arguments for offering genetic counseling
and possible testing to interested 18 to 20 year-olds at high risk for car-
rying a BRCAmutation. For example, there are potential medical impli-
cations to them even though national guidelines do not recommend
screening with annual clinical breast exams and breast MRI exams
until age 25 (National Comprehensive Cancer Network Inc., 2015) and
risk reducing mastectomy is rarely, if ever, performed in 18 to 20
year-olds. However, young women may still wish to make informed
decisions about other medical issues such as oral contraceptive use
(Hoskins et al., 2014). Oral contraceptives decrease ovarian cancer riskDOI of original article: http://dx.doi.org/10.1016/j.ygyno.2014.09.009.
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(Moorman et al., 2013). Thus, not only is oral contraceptive use not con-
traindicated in BRCA carriers, but it may be encouraged by some clini-
cians as a strategy to reduce ovarian cancer risk (Narod, 2004). Some
young women may not be knowledgeable about this information and
may pursue testing to make a decision about use of hormonal birth
control.
Because 18 to 20 year-olds are of reproductive age, it is also
important that they bemade aware of reproductive options such as pre-
implantation genetic diagnosis (National Comprehensive Cancer
Network Inc., 2015). Although childbearing may not be imminent for
women in this age group, they should still be informed about reproduc-
tive options because relationship formation and life planning may be
prominent tasks of this life stage (Werner-Lin et al., 2012).
However, we assert that the most compelling argument against a
policy of not testing 18 to 20 year-oldwomen is that, with proper genet-
ic counseling, these individuals may derive signiﬁcant psychological re-
lief from testing. A critical part of the genetic counseling process is to
assess psychological concerns and to provide individualized resources
and support (Riley et al., 2012). Research has demonstrated that
womenwho test negative for a familial BRCAmutation experience a sig-
niﬁcant reduction in distress compared to pre-test levels (Beran et al.,
2008; Schwartz et al., 2002). Moreover, distress among women who
test positive does not appear to reach clinically signiﬁcant levels or
to persist by the one-year mark after testing (Beran et al., 2008;
Schwartz et al., 2002). Althoughwomenwho test negative for a familial
mutation are likely to experience the most signiﬁcant psychological
beneﬁts from testing, the relief from uncertainty may be empowering
even to those who test positive.
We acknowledge that little research has been done characterizing
young at-risk women speciﬁcally and their psychological outcomes fol-
lowing genetic testing. Concerns have been raised about how these
young women may cope with genetic testing results (Werner-Lin et al.,
2012). However, there is no evidence that they are likely to suffer adverse
consequences from genetic testing when it is pursued in the setting of
comprehensive genetic counseling. Because young adult women are in-
creasingly seeking out genetic testing for hereditary cancer risk, contin-
ued research to assess best practices and outcomes is important.
A cornerstone of genetic counseling is to facilitate and foster patient
autonomy. After genetic counseling, some youngwomenmay choose to
pursue genetic testing, and others may defer it until they feel more pre-
pared to assimilate the results, both psychologically and/or medically.
Genetic counseling is designed to provide information and support
regardless of a woman's testing decision. Genetic counseling is also an
opportune time to correct misinformation about risk and risk manage-
ment, and for young women to discuss concerns about their worries,
plans, family formation, and existing family dynamics (Hoskins et al.,
2014; Hoskins andWerner-Lin, 2013).We believe that a blanket recom-
mendation against offering genetic testing to young adult women com-
promises their autonomy and may deter them from pursuing genetic
counseling.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
45CorrespondenceIn sum, we support a recommendation that adults who are at in-
creased risk for hereditary cancer syndromes, including 18 to 20 year-
olds, should be offered genetic counseling. This process enables patients
to make informed decisions about genetic testing and management
based on the associated potential beneﬁts, limitations, and risks, as
well as their own values, preferences, and goals. Therefore, we encour-
agemembers of the SGO Clinical Practice Committee to reconsider their
recommendations in this regard.
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